{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:08:24Z","timestamp":1781773704668,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T00:00:00Z","timestamp":1535846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["762\/3-2"],"award-info":[{"award-number":["762\/3-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"European Union's Seventh Framework Programme","doi-asserted-by":"publisher","award":["602783"],"award-info":[{"award-number":["602783"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.neo.2018.08.009","type":"journal-article","created":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T09:17:41Z","timestamp":1537694261000},"page":"1135-1143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2766-1688","authenticated-orcid":false,"given":"Albert","family":"Job","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Maria","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"von Wenserski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-6855","authenticated-orcid":false,"given":"Brigitte","family":"Lankat-Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Gress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Gallmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.neo.2018.08.009_bb0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.neo.2018.08.009_bb0010","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly (ADP-ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neo.2018.08.009_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors\u2013moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.neo.2018.08.009_bb0020","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.dnarep.2007.02.015","article-title":"The ATR pathway: fine-tuning the fork","volume":"6","author":"Paulsen","year":"2007","journal-title":"DNA Repair"},{"issue":"8","key":"10.1016\/j.neo.2018.08.009_bb0025","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6811","key":"10.1016\/j.neo.2018.08.009_bb0030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/35044005","article-title":"The DNA damage response: putting checkpoints in perspective","volume":"408","author":"Zhou","year":"2000","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neo.2018.08.009_bb0035","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/stem.595","article-title":"Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction","volume":"29","author":"Gallmeier","year":"2011","journal-title":"Stem Cells"},{"issue":"5","key":"10.1016\/j.neo.2018.08.009_bb0040","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/ph3051311","article-title":"Prospects for the use of ATR inhibitors to treat cancer","volume":"3","author":"Wagner","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.neo.2018.08.009_bb0045","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.6857","article-title":"A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers","volume":"7","author":"Hocke","year":"2016","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.neo.2018.08.009_bb0050","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/sj.onc.1210049","article-title":"Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation","volume":"26","author":"Hurley","year":"2007","journal-title":"Oncogene"},{"issue":"35","key":"10.1016\/j.neo.2018.08.009_bb0055","doi-asserted-by":"crossref","first-page":"26179","DOI":"10.1016\/S0021-9258(19)74297-5","article-title":"Enzymatic characterization of the individual mammalian primase subunits reveals a biphasic mechanism for initiation of DNA replication","volume":"268","author":"Copeland","year":"1993","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.neo.2018.08.009_bb0060","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1146\/annurev.biochem.67.1.721","article-title":"The DNA replication fork in eukaryotic cells","volume":"67","author":"Waga","year":"1998","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"10.1016\/j.neo.2018.08.009_bb0065","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4161\/cbt.6.5.3978","article-title":"Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer","volume":"6","author":"Gallmeier","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.neo.2018.08.009_bb0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1128\/MCB.26.1.39-49.2006","article-title":"Recruitment of DNA damage checkpoint proteins to damage in transcribed and nontranscribed sequences","volume":"26","author":"Jiang","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.neo.2018.08.009_bb0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","article-title":"A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry","volume":"139","author":"Nicoletti","year":"1991","journal-title":"J Immunol Methods"},{"issue":"42","key":"10.1016\/j.neo.2018.08.009_bb0080","doi-asserted-by":"crossref","first-page":"73240","DOI":"10.18632\/oncotarget.17291","article-title":"Germline mutations in pancreatic cancer and potential new therapeutic options","volume":"8","author":"Pihlak","year":"2017","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.neo.2018.08.009_bb0085","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.neo.2018.08.009_bb0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-016-0368-1","article-title":"Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non\u2013small cell lung cancer","volume":"34","author":"Scagliotti","year":"2016","journal-title":"Invest New Drugs"},{"issue":"9","key":"10.1016\/j.neo.2018.08.009_bb0095","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2018.08.009_bb0100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.leukres.2017.09.005","article-title":"Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia","volume":"61","author":"Webster","year":"2017","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.neo.2018.08.009_bb0105","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1038\/oncsis.2013.35","article-title":"Epigenetic and genetic features of 24 colon cancer cell lines","volume":"2","author":"Ahmed","year":"2013","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.neo.2018.08.009_bb0110","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0959-8049(99)00206-3","article-title":"Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines","volume":"35","author":"Ku","year":"1999","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.neo.2018.08.009_bb0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02890431","article-title":"Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma","volume":"61","author":"Els\u00e4sser","year":"1992","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"issue":"5547","key":"10.1016\/j.neo.2018.08.009_bb0120","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1065521","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.neo.2018.08.009_bb0125","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4161\/cc.26062","article-title":"Wee1 kinase as a target for cancer therapy","volume":"12","author":"Do","year":"2013","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.neo.2018.08.009_bb0130","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 kinase in cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"10.1016\/j.neo.2018.08.009_bb0135","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neo.2018.08.009_bb0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-94-007-4572-8_9","article-title":"The Pol \u03b1-primase complex","volume":"62","author":"Pellegrini","year":"2012","journal-title":"Subcell Biochem"},{"issue":"4","key":"10.1016\/j.neo.2018.08.009_bb0145","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ng1129","article-title":"A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome","volume":"33","author":"O'Driscoll","year":"2003","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.neo.2018.08.009_bb0150","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1535-7163.MCT-06-0679","article-title":"Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival","volume":"6","author":"Wilsker","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.neo.2018.08.009_bb0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/embo-reports\/kvd018","article-title":"Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis","volume":"1","author":"Molinari","year":"2000","journal-title":"EMBO Rep"},{"issue":"Pt 14","key":"10.1016\/j.neo.2018.08.009_bb0160","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1242\/jcs.115.14.2829","article-title":"Prolonged arrest of mammalian cells at the G1\/S boundary results in permanent S phase stasis","volume":"115","author":"Borel","year":"2002","journal-title":"J Cell Sci"},{"issue":"4","key":"10.1016\/j.neo.2018.08.009_bb0165","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1016167228059","article-title":"Initiator caspases in apoptosis signaling pathways","volume":"7","author":"Chen","year":"2002","journal-title":"Apoptosis"},{"issue":"4","key":"10.1016\/j.neo.2018.08.009_bb0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7150\/ijbs.2.161","article-title":"Murine Wee1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development","volume":"2","author":"Tominaga","year":"2006","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.neo.2018.08.009_bb0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/1541-7786.MCR-11-0500","article-title":"WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis","volume":"10","author":"Garimella","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"4","key":"10.1016\/j.neo.2018.08.009_bb0180","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/gim.2015.75","article-title":"POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and\/or polyposis: review of reported cases and recommendations for genetic testing and surveillance","volume":"18","author":"Bellido","year":"2016","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.neo.2018.08.009_bb0185","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ng.2503","article-title":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","volume":"45","author":"Palles","year":"2013","journal-title":"Nat Genet"},{"issue":"13","key":"10.1016\/j.neo.2018.08.009_bb0190","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1093\/hmg\/ddu058","article-title":"New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis","volume":"23","author":"Valle","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.neo.2018.08.009_bb0195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/(SICI)1098-2264(199909)26:1<62::AID-GCC9>3.0.CO;2-F","article-title":"Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma","volume":"26","author":"Yotov","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.neo.2018.08.009_bb0200","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431X20154861","article-title":"Gene expression profiling analysis of lung adenocarcinoma","volume":"49","author":"Xu","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.neo.2018.08.009_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.31788","article-title":"DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2\/M cell cycle checkpoint","author":"Lee","year":"2018","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.neo.2018.08.009_bb0215","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood-2003-05-1577","article-title":"ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis","volume":"103","author":"Garattini","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.neo.2018.08.009_bb0220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nchembio.2082","article-title":"The antitumor toxin CD437 is a direct inhibitor of DNA polymerase \u03b1","volume":"12","author":"Han","year":"2016","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.neo.2018.08.009_bb0225","first-page":"39","article-title":"Mechanism of action of the atypical retinoid ST1926 in colorectal cancer: DNA damage and DNA polymerase \u03b1","volume":"8","author":"Abdel-Samad","year":"2018","journal-title":"Am J Cancer Res"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558618303853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558618303853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T12:48:49Z","timestamp":1662122929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558618303853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1476558618303853"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2018.08.009","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2018.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}